CL2025001237A1 - Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos - Google Patents

Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos

Info

Publication number
CL2025001237A1
CL2025001237A1 CL2025001237A CL2025001237A CL2025001237A1 CL 2025001237 A1 CL2025001237 A1 CL 2025001237A1 CL 2025001237 A CL2025001237 A CL 2025001237A CL 2025001237 A CL2025001237 A CL 2025001237A CL 2025001237 A1 CL2025001237 A1 CL 2025001237A1
Authority
CL
Chile
Prior art keywords
autoantibody
treatment
immunoglobulin
multispecific molecules
induced diseases
Prior art date
Application number
CL2025001237A
Other languages
English (en)
Inventor
Siva Charan Devanaboyina Venkata
Li Peng
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2025001237A1 publication Critical patent/CL2025001237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a moléculas multiespecíficas que se unen a inmunoglobulina y a una diana de reciclaje. La unión de la inmunoglobulina y una diana de reciclaje da como resultado la degradación de la inmunoglobulina y, en ciertas realizaciones, el reciclaje de la molécula multiespecífica. Se cree que las moléculas multiespecíficas de la presente invención son útiles en el tratamiento de enfermedades inducidas por autoanticuerpos.
CL2025001237A 2022-10-26 2025-04-25 Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos CL2025001237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263419549P 2022-10-26 2022-10-26

Publications (1)

Publication Number Publication Date
CL2025001237A1 true CL2025001237A1 (es) 2025-06-23

Family

ID=88874631

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001237A CL2025001237A1 (es) 2022-10-26 2025-04-25 Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos

Country Status (9)

Country Link
EP (1) EP4608864A1 (es)
JP (1) JP2026500893A (es)
KR (1) KR20250094708A (es)
CN (1) CN120359240A (es)
AU (1) AU2023367846A1 (es)
CL (1) CL2025001237A1 (es)
IL (1) IL320335A (es)
MX (1) MX2025004882A (es)
WO (1) WO2024092033A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146152A1 (zh) * 2024-01-04 2025-07-10 上海宝济药业股份有限公司 一种药物组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
HRP20000714B1 (en) 1998-04-21 2006-03-31 Micromet Ag NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
CA3045797A1 (en) * 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
WO2020104496A1 (en) * 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
MX2021007376A (es) * 2018-12-19 2021-09-21 Univ Leland Stanford Junior Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados.
WO2022115715A1 (en) * 2020-11-30 2022-06-02 Fred Hutchinson Cancer Research Center Compositions and methods for selective depletion of target molecules
JP2024503687A (ja) * 2021-01-19 2024-01-26 ノバルティス アーゲー 細胞外標的の分解

Also Published As

Publication number Publication date
IL320335A (en) 2025-06-01
KR20250094708A (ko) 2025-06-25
WO2024092033A1 (en) 2024-05-02
MX2025004882A (es) 2025-06-02
CN120359240A (zh) 2025-07-22
JP2026500893A (ja) 2026-01-09
EP4608864A1 (en) 2025-09-03
AU2023367846A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CL2022003077A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
CL2025001237A1 (es) Moléculas multiespecíficas para el aclaramiento de inmunoglobulinas en el tratamiento de enfermedades inducidas por autoanticuerpos
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
MX2022002977A (es) Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
MX2020014158A (es) Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos.
CO2019003133A2 (es) Construcciones de inmunoglobulina heterodiméricas y métodos de preparación de las mismas
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
MX2021014472A (es) Moleculas de union a tigit y pd-1/tigit.
BR112017002703A2 (pt) anticorpos específicos de mmp9.
CL2023000683A1 (es) Moléculas de unión a b7-h4 terapéuticas
MX2011010707A (es) Anticuerpos dkk-1.
CO2022003703A2 (es) Conjugados terapéuticos
ECSP24044371A (es) Moléculas de anticuerpo y conjugados
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
MX2024008174A (es) Metodos para tratar el cancer urotelial musculo-invasivo o el cancer de vejiga musculo-invasivo con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12
MX2025000437A (es) Inmunoconjugados de epcam y usos de estos
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
MX2021009533A (es) Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo.
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
BR112022013575A2 (pt) Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos
MX2023004089A (es) Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.
DOP2025000023A (es) Proteínas de unión a nkg2d, cd16 y ceacam5
MX2024006205A (es) Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria.